Literature DB >> 28158562

Increased cytoplasmic TDP-43 reduces global protein synthesis by interacting with RACK1 on polyribosomes.

Arianna Russo1, Raffaella Scardigli2,3, Federico La Regina3, Melissa E Murray4, Nicla Romano1, Dennis W Dickson4, Benjamin Wolozin5,6, Antonino Cattaneo7, Marcello Ceci1.   

Abstract

TDP-43 is a well known RNA binding protein involved in the pathogenesis of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Dementia (FTLD). In physiological conditions, TDP-43 mainly localizes in the nucleus and shuttles, at least in neurons, to the cytoplasm to form TDP-43 RNA granules. In the nucleus, TDP-43 participates to the expression and splicing of RNAs, while in the cytoplasm its functions range from transport to translation of specific mRNAs. However, if loss or gain of these TDP-43 functions are affected in ALS/FTLD pathogenesis is not clear. Here, we report that TDP-43 localizes on ribosomes not only in primary neurons but also in SH-SY5Y human neuroblastoma cells. We find that binding of TDP-43 to the translational machinery is mediated by an interaction with a specific ribosomal protein, RACK1, and that an increase in cytoplasmic TDP-43 represses global protein synthesis, an effect which is rescued by overexpression of RACK1. Ribosomal loss of RACK1, which excludes TDP-43 from the translational machinery, remarkably reduces formation of TDP-43 cytoplasmic inclusions in neuroblastoma cells. Finally, we corroborate the interaction between TDP-43 and RACK1 on polyribosomes of neuroblastoma cells with mis-localization of RACK1 on TDP-43 positive cytoplasmic inclusions in motor neurons of ALS patients. In conclusions, results from this study suggest that TDP-43 represents a translational repressor not only for specific mRNAs but for overall translation and that its binding to polyribosomes through RACK1 may promote, under conditions inducing ALS pathogenesis, the formation of cytoplasmic inclusions.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28158562      PMCID: PMC6075552          DOI: 10.1093/hmg/ddx035

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  60 in total

1.  TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells.

Authors:  Claudia Colombrita; Elisa Onesto; Francesca Megiorni; Antonio Pizzuti; Francisco E Baralle; Emanuele Buratti; Vincenzo Silani; Antonia Ratti
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

2.  Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats.

Authors:  Cao Huang; Jianbin Tong; Fangfang Bi; Hongxia Zhou; Xu-Gang Xia
Journal:  J Clin Invest       Date:  2011-12-12       Impact factor: 14.808

Review 3.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

4.  Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma.

Authors:  Yuanyuan Ruan; Linlin Sun; Yuqing Hao; Lijing Wang; Jiejie Xu; Wen Zhang; Jianhui Xie; Liang Guo; Lei Zhou; Xiaojing Yun; Hongguang Zhu; Aiguo Shen; Jianxin Gu
Journal:  J Clin Invest       Date:  2012-06-01       Impact factor: 14.808

5.  Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis.

Authors:  Sami J Barmada; Gaia Skibinski; Erica Korb; Elizabeth J Rao; Jane Y Wu; Steven Finkbeiner
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

6.  Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).

Authors:  Eva Bentmann; Manuela Neumann; Sabina Tahirovic; Ramona Rodde; Dorothee Dormann; Christian Haass
Journal:  J Biol Chem       Date:  2012-05-04       Impact factor: 5.157

7.  RACK1 is a ribosome scaffold protein for β-actin mRNA/ZBP1 complex.

Authors:  Marcello Ceci; Kristy Welshhans; Maria Teresa Ciotti; Rossella Brandi; Chiara Parisi; Francesca Paoletti; Luana Pistillo; Gary J Bassell; Antonino Cattaneo
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

8.  The ribosomal protein RACK1 is required for microRNA function in both C. elegans and humans.

Authors:  Guillaume Jannot; Sarah Bajan; Nellie J Giguère; Samir Bouasker; Isabelle H Banville; Sandra Piquet; Gyorgy Hutvagner; Martin J Simard
Journal:  EMBO Rep       Date:  2011-04-28       Impact factor: 8.807

9.  RNA-binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2 alpha to the assembly of mammalian stress granules.

Authors:  N L Kedersha; M Gupta; W Li; I Miller; P Anderson
Journal:  J Cell Biol       Date:  1999-12-27       Impact factor: 10.539

10.  Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models.

Authors:  Hyung-Jun Kim; Alya R Raphael; Eva S LaDow; Leeanne McGurk; Ross A Weber; John Q Trojanowski; Virginia M-Y Lee; Steven Finkbeiner; Aaron D Gitler; Nancy M Bonini
Journal:  Nat Genet       Date:  2013-12-15       Impact factor: 38.330

View more
  34 in total

Review 1.  The Role of TDP-43 in Neurodegenerative Disease.

Authors:  Yan-Zhe Liao; Jing Ma; Jie-Zhi Dou
Journal:  Mol Neurobiol       Date:  2022-05-02       Impact factor: 5.590

Review 2.  LISTERIN E3 Ubiquitin Ligase and Ribosome-Associated Quality Control (RQC) Mechanism.

Authors:  Ribhav Mishra; Anurag Bansal; Amit Mishra
Journal:  Mol Neurobiol       Date:  2021-09-29       Impact factor: 5.590

Review 3.  TDP43 ribonucleoprotein granules: physiologic function to pathologic aggregates.

Authors:  Giulia Ada Corbet; Joshua R Wheeler; Roy Parker; Kaitlin Weskamp
Journal:  RNA Biol       Date:  2021-08-19       Impact factor: 4.766

4.  Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics - An AI-Enabled Biological Target Discovery Platform.

Authors:  Frank W Pun; Bonnie Hei Man Liu; Xi Long; Hoi Wing Leung; Geoffrey Ho Duen Leung; Quinlan T Mewborne; Junli Gao; Anastasia Shneyderman; Ivan V Ozerov; Ju Wang; Feng Ren; Alexander Aliper; Evelyne Bischof; Evgeny Izumchenko; Xiaoming Guan; Ke Zhang; Bai Lu; Jeffrey D Rothstein; Merit E Cudkowicz; Alex Zhavoronkov
Journal:  Front Aging Neurosci       Date:  2022-06-28       Impact factor: 5.702

5.  TAR DNA-Binding Protein 43 and Disrupted in Schizophrenia 1 Coaggregation Disrupts Dendritic Local Translation and Mental Function in Frontotemporal Lobar Degeneration.

Authors:  Ryo Endo; Noriko Takashima; Yoko Nekooki-Machida; Yusuke Komi; Kelvin Kai-Wan Hui; Masaki Takao; Hiroyasu Akatsu; Shigeo Murayama; Akira Sawa; Motomasa Tanaka
Journal:  Biol Psychiatry       Date:  2018-03-29       Impact factor: 13.382

6.  A role of cellular translation regulation associated with toxic Huntingtin protein.

Authors:  Hiranmay Joag; Vighnesh Ghatpande; Meghal Desai; Maitheli Sarkar; Anshu Raina; Mrunalini Shinde; Ruta Chitale; Ankita Deo; Tania Bose; Amitabha Majumdar
Journal:  Cell Mol Life Sci       Date:  2019-12-03       Impact factor: 9.261

Review 7.  Dynamic duo - FMRP and TDP-43: Regulating common targets, causing different diseases.

Authors:  Diana Ferro; Stephen Yao; Daniela C Zarnescu
Journal:  Brain Res       Date:  2018-04-30       Impact factor: 3.252

Review 8.  RNA-binding proteins in neurological development and disease.

Authors:  Shavanie Prashad; Pallavi P Gopal
Journal:  RNA Biol       Date:  2020-08-30       Impact factor: 4.652

9.  Trends in Understanding the Pathological Roles of TDP-43 and FUS Proteins.

Authors:  Emanuele Buratti
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 10.  RACK1 regulates neural development.

Authors:  Leah Kershner; Kristy Welshhans
Journal:  Neural Regen Res       Date:  2017-07       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.